EmphyCorps Proprietary N115

N115

Up until the recent acclaim of EmphyCorp's proprietary technology, N115, the primary treatment for asthmatic bronchitis and chronic obstructive pulmonary diseases was the use of corticosteroids. Corticosteroids are typically involved in a very wide range of physiological processes such as the body's stress response, immune response and regulation of inflammation, carbohydrate metabolism, protein catabolism, blood electrolyte levels and overall behavior.

However, corticosteroids are certainly not a reliable form of treatment; as well documented studies have shown that any prolonged use of corticosteroids may have serious side effects including the potential for fatality. Other marketed drugs that directly treat pulmonary diseases are also reported to produce substantial damage to the body, mainly in areas such as the central nervous system, cardiovascular system, respiratory system and an abrupt disruption within the gastrointestinal system. Until this day, EmphyCorp's N115 remains one of the most effective and one of the safest on the entire market. With this form of unique technology, patients are no longer prone to experiencing the common complications to that of corticosteroids.

Each treatment involving synthetic pharmaceutical drugs that feature corticosteroid-like effects should come with a flamboyant warning label. These corticosteroid-like effects are used to "treat" a variety of conditions, mainly ranging from brain tumors to that of an individual's case of skin disease. Both clinical and experimental evidence has indicated that corticosteroids are capable of causing permanent eye damage by inducing a form of central serous retinopathy, also recognized as central serous chorioretinopathy that causes an optical disease that causes visual impairment in one eye.

EmphyCorp's technology is not considered a pipe dream, as over thirteen publications from major independent research institutes confirmed during the calendar year of 1998, the initial scientific premise on the origin of lung diseases upon which EmphyCorp's N115 proprietary technology and delivery system are based. There has long been a substantial amount of bona fide facts that depict N115 as an effective and far safer method than that of a steroidal treatment. Currently, EmphyCorp has filed and been issued around eight different patents, ranging from the year 1998 until 2009. It should be duly noted that the F.D.A. has determined that N115 has shown sufficient safety in terms of toxicology and clinical data, enough to precede with the multi-dose, prolonged use clinical trials.